205 related articles for article (PubMed ID: 30877872)
1. Unexpected worsening of pemphigus vulgaris after rituximab: A report of three cases.
Mahmoudi H; Balighi K; Tavakolpour S; Daneshpazhooh M
Int Immunopharmacol; 2019 Jun; 71():40-42. PubMed ID: 30877872
[TBL] [Abstract][Full Text] [Related]
2. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up.
Ahmed AR; Nguyen T; Kaveri S; Spigelman ZS
Int Immunopharmacol; 2016 May; 34():25-31. PubMed ID: 26919279
[TBL] [Abstract][Full Text] [Related]
3. Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?
Balighi K; Daneshpazhooh M; Mahmoudi H; Badakhsh M; Teimourpour A; Ehsani AH; Azizpour A; Akbari Z; Mahdavinia M; Ghasemiadl M; Tavakolpour S
Arch Dermatol Res; 2019 Jan; 311(1):63-69. PubMed ID: 30506422
[TBL] [Abstract][Full Text] [Related]
4. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review.
Tavakolpour S; Mahmoudi H; Balighi K; Abedini R; Daneshpazhooh M
Int Immunopharmacol; 2018 Jan; 54():131-138. PubMed ID: 29132070
[TBL] [Abstract][Full Text] [Related]
5. Rituximab treatment in pemphigus vulgaris: effect on circulating Tregs.
El-Zawahry B; Bassiouny D; Hegazy R; Gawdat H; Shalaby S; Khorshied M; Saleh MA
Arch Dermatol Res; 2017 Sep; 309(7):551-556. PubMed ID: 28631092
[TBL] [Abstract][Full Text] [Related]
6. Iranian guideline for rituximab therapy in pemphigus patients.
Daneshpazhooh M; Balighi K; Mahmoudi H; Tavakolpour S; Abedini R; Soori T; Ehsani AH; Ghiasi M; Noormohammadpour P; Ghandi N; Lajevardi V; Sadeghinia A; Nasimi M; Azizpour A; Chams-Davatchi C
Dermatol Ther; 2019 Sep; 32(5):e13016. PubMed ID: 31269316
[TBL] [Abstract][Full Text] [Related]
7. Clinical resolution of pemphigus vulgaris on rituximab.
Cusick E; Silverstein D
Dermatol Online J; 2017 Sep; 23(9):. PubMed ID: 29469734
[TBL] [Abstract][Full Text] [Related]
8. Comparison of rituximab and intravenous immunoglobulin in the treatment of autoimmune bullous diseases: Real-life data from a single centre.
Huseynova Terzi L; Akdogan N; Dogan Gunaydin S; Atakan N
Int J Clin Pract; 2021 Dec; 75(12):e14955. PubMed ID: 34610193
[TBL] [Abstract][Full Text] [Related]
9. Treatment strategies for pemphigus vulgaris in Japan.
Hashimoto T
Expert Opin Pharmacother; 2008 Jun; 9(9):1519-30. PubMed ID: 18518782
[TBL] [Abstract][Full Text] [Related]
10. Current biologics in treatment of pemphigus foliaceus: a systematic review.
Carver CA; Kalesinskas M; Ahmed AR
Front Immunol; 2023; 14():1267668. PubMed ID: 37901249
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study.
Toosi R; Mahmoudi H; Balighi K; Teimourpour A; Alaeen H; Shaghaghi M; Abedini R; Daneshpazhooh M
J Dermatolog Treat; 2021 Feb; 32(1):33-40. PubMed ID: 31074302
[No Abstract] [Full Text] [Related]
12. Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?
Tavakolpour S
Int Immunopharmacol; 2017 Dec; 53():133-142. PubMed ID: 29107213
[TBL] [Abstract][Full Text] [Related]
13. Rituximab therapy in pediatric pemphigus patients: A retrospective analysis of five Turkish patients and review of the literature.
Bilgic-Temel A; Özgen Z; Harman M; Kapıcıoğlu Y; Uzun S
Pediatr Dermatol; 2019 Sep; 36(5):646-650. PubMed ID: 31355479
[TBL] [Abstract][Full Text] [Related]
14. Rituximab and low dose oral immune modulating treatment to maintain a sustained response in severe pemphigus patients.
Keeley JM; Bevans SL; Jaleel T; Sami N
J Dermatolog Treat; 2019 Jun; 30(4):340-345. PubMed ID: 30086663
[No Abstract] [Full Text] [Related]
15. A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab.
Saleh MA
J Am Acad Dermatol; 2018 Jul; 79(1):97-103. PubMed ID: 29408700
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs.
Grando SA
Int J Dermatol; 2019 Jan; 58(1):114-125. PubMed ID: 30047585
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration.
Mahmoudi H; Tavakolpour S; Balighi K; Farid AS; Nili A; Jan D; Daneshpazhooh M
Dermatol Ther; 2021 Jan; 34(1):e14633. PubMed ID: 33280226
[TBL] [Abstract][Full Text] [Related]
18. The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review.
Kridin K; Ahmed AR
Expert Opin Biol Ther; 2021 Apr; 21(4):443-454. PubMed ID: 33455475
[TBL] [Abstract][Full Text] [Related]
19. Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience.
Braun-Moscovici Y; Butbul-Aviel Y; Guralnik L; Toledano K; Markovits D; Rozin A; Nahir MA; Balbir-Gurman A
Rheumatol Int; 2013 Jun; 33(6):1495-504. PubMed ID: 23239037
[TBL] [Abstract][Full Text] [Related]
20. Pemphigus vulgaris: approach to treatment.
Sinha AA; Hoffman MB; Janicke EC
Eur J Dermatol; 2015 Apr; 25(2):103-13. PubMed ID: 25547117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
